Search Within

Nicole Alexa Schreiber

Formats
  1. Meeting Abstract (20)
  2. Journal Article (8)
Groups
  1. Department of Medicine (28)
  2. Genitourinary Oncology Service (28)
  3. Solid Tumor Oncology Division (28)
  4. Epidemiology and Biostatistics (9)
  5. Biostatistics Service (7)
  6. Molecular Imaging and Therapy Service (4)

More Groups

People
  1. Howard Scher (27)
  2. Martin Fleisher (17)
  3. Brigit McLaughlin (11)
  4. Daniel Danila (11)
  5. Glenn Heller (7)
  6. Richard Bambury (6)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2019 (1)
  4. 2018 (5)
  5. 2017 (5)
  6. 2016 (6)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Cancer Research (3)
  3. JAMA Oncology (3)
  4. Annals of Oncology (2)
  5. Cancer Prevention Research (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. American Association for Cancer Research (5)
  3. American Medical Association (3)
  4. Elsevier Science, Inc. (2)
  5. Oxford University Press (2)
  6. Elsevier Inc. (1)

More Publishers

Results (28)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clonal hematopoiesis and risk of lethal prostate cancer: a prospective cohort study with long-term follow-up
    Meeting Abstract

    Stopsack, K. H.; Chan, I. C.; Schmidt, E.; Panchot, A.; McNulty, S.; Schreiber, N. A.; Zhang, Y. W.; Penney, K. L.; Berger, M. F.; Diaz, L. A.; more...
    Cancer Prevention Research (2023)

    Fulltext@MSK | Save
  • Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancer
    Journal Article

    Lu, D.; Krupa, R.; Harvey, M.; Graf, R. P.; Schreiber, N.; Barnett, E.; Carbone, E.; Jendrisak, A.; Gill, A.; Orr, S.; more...
    Journal of Circulating Biomarkers (2020)

    Fulltext@MSK | Save
  • CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)
    Meeting Abstract

    Scher, H. I.; Lee, J.; Dago, A. E.; Barnett, E.; Sutton, R.; Carbone, E.; Schreiber, N. A.; Hullings, M.; Ebrahim, N.; Landers, M. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Graf, R. P.; Dago, A. E.; Lee, J.; Sutton, R.; Schreiber, N. A.; Hullings, M.; Jendrisak, A.; Wang, Y.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples
    Meeting Abstract

    Scher, H. I.; Dago, A. E.; Lee, J.; Sutton, R.; Graf, R. P.; Schreiber, N. A.; Hullings, M.; Wang, Y.; Landers, M. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial
    Journal Article

    Autio, K. A.; Dreicer, R.; Anderson, J.; Garcia, J. A.; Alva, A.; Hart, L. L.; Milowsky, M. I.; Posadas, E. M.; Ryan, C. J.; Graf, R. P.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Jayaram, A.; Winquist, E.; McLaughlin, B.; Lu, D.; Fleisher, M.; Orr, S.; Lowes, L.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save
  • Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A)
    Meeting Abstract

    Scher, H. I.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R. P.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx)
    Meeting Abstract

    Dittamore, R. V.; Jendrisak, A.; Schreiber, N. A.; McLaughlin, B.; Graf, R.; Rodriguez, A.; Fleisher, M.; Lee, J.; Kelvin, J.; Wang, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save